| Literature DB >> 26991997 |
Yang Liu1, Yanzhen Yin1, Jingya Zhang1, Krystle Nomie2, Liang Zhang2, Dezhi Yang1, Michael L Wang2, Guisen Zhao1.
Abstract
A series of 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives was synthesized and evaluated as Akt inhibitors by optimization of a weak screening lead (1). Typically, compounds 5q and 5t significantly improved the Akt1 inhibitory potency with IC50 values of 18.0 and 21.3 nM, respectively, with desirable antiproliferative effect against the cell lines LNCaP and PC-3. The inhibitors 5q and 5t might serve as lead compounds for further exploration of Akt inhibitors as anticancer agents.Entities:
Keywords: Akt; Anticancer; Docking; Pyrrolopyrimidines
Mesh:
Substances:
Year: 2016 PMID: 26991997 DOI: 10.1002/ardp.201500427
Source DB: PubMed Journal: Arch Pharm (Weinheim) ISSN: 0365-6233 Impact factor: 3.751